Last reviewed · How we verify
A5
A5 is a medication that works by inhibiting the action of a specific enzyme.
A5 is a medication that works by inhibiting the action of a specific enzyme. Used for Type 2 diabetes, Heart failure.
At a glance
| Generic name | A5 |
|---|---|
| Also known as | T10/C2 - CBD 2%, THC 10% |
| Sponsor | Breath of Life International Pharma Ltd |
| Drug class | SGLT2 inhibitor |
| Target | SGLT2 |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | FDA-approved |
Mechanism of action
A5 binds to and inhibits the activity of the enzyme, leading to a decrease in the production of a certain substance in the body. This decrease in substance production is associated with therapeutic benefits in the treatment of various conditions.
Approved indications
- Type 2 diabetes
- Heart failure
Common side effects
- Increased risk of diabetic ketoacidosis
- Increased risk of genital amputation
- Increased risk of urinary tract infections
Key clinical trials
- WEB-BASED FILIAL THERAPY IN PEDIATRIC CANCER (NA)
- A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001) (PHASE3)
- The Effects of 5G Radiation on Skin (NA)
- Sleep Loss and Circadian Misalignment - Mechanisms of Insulin Resistance (PHASE4)
- Implementation Science to Enhance HIV Testing Services During Emergency Care in Kenya (NA)
- Examining the Effectiveness of Exercise Training After Cervical Laminoplasty Surgery (NA)
- "Effect of Pre-Spinal Mindfulness-Based Breathing Exercise on Hemodynamic Response in Elective Cesarean Section" (NA)
- A Norwegian Trial Comparing Treatment Strategies for Carpal Tunnel Syndrome (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- A5 CI brief — competitive landscape report
- A5 updates RSS · CI watch RSS
- Breath of Life International Pharma Ltd portfolio CI